Anti-Monkeypox virus (MPV) A33 human monoclonal neutralizing antibody (IgG1) for Therapeutics (positive control in vaccine development，benchmark in neutralizing antibodies discovery) and Diagnosis

Cat No.: GMP-MPV-Tg01-nAb001,GMP-MPV-Tg01-nAb002,GMP-MPV-Tg01-nAb003,GMP-MPV-Tg01-nAb004

The A33, L1, B5, and A25 genes encode the four proteins viz. A33, L1, B5, and A25, respectively. All of these immunogens are highly homologous (> 93%) between variola, monkeypox, and vaccinia. A33 is a type II integral membrane protein present as a dimer on the EV. Some evidence suggests A33 has a role in facilitating antibody-resistant cell-to-cell spread of orthopoxviruses. The A28 gene of vaccinia virus is conserved in all poxviruses and encodes a protein that is anchored to the surface of infectious intracellular mature virions (IMV) and consequently lies beneath the additional envelope of extracellular virions and required for the virus propagation. The product of the H3L gene, p35, is another envelope protein that is an immunodominant antigen found on orthopoxvirus. Strong immune responses to p35 protein have been detected in mice, sheep, rabbits, and humans. It has also been shown that the monoclonal antibodies against A28, A33, B5, L1 and H3 are cross protective cross-protective for variola, monkeypox, and vaccinia.

GeneMedi has quickly screened these neutralizing antibodies, which are valid for Monkeypox virus (MPV). They could be used as Benchmark Antibody, assist in neutralizing antibody discovery and development. They could also be used for Diagnosis. It should be noted that these antibodies have cross reactivity with vaccinia virus (VACV) and other Pox viruses.



Order information

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-MPV-Tg01-nAb001 1mg 5090
GMP-MPV-Tg01-nAb001 10mg 35890
GMP-MPV-Tg01-nAb001 100mg 228090
GMP-MPV-Tg01-nAb002 1mg 5090
GMP-MPV-Tg01-nAb002 10mg 35890
GMP-MPV-Tg01-nAb002 100mg 228090
GMP-MPV-Tg01-nAb003 1mg 5090
GMP-MPV-Tg01-nAb003 10mg 35890
GMP-MPV-Tg01-nAb003 100mg 228090
GMP-MPV-Tg01-nAb004 1mg 5090
GMP-MPV-Tg01-nAb004 10mg 35890
GMP-MPV-Tg01-nAb004 100mg 228090
GMP-MPV-Tg01-nAb001~nAb004 ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Cat No. of Pruducts GMP-MPV-Tg01-nAb001, GMP-MPV-Tg01-nAb002, GMP-MPV-Tg01-nAb003, GMP-MPV-Tg01-nAb004
Product Name Anti-MPV (A33) human monoclonal neutralizing antibody (IgG1)
Target A33
Expression platform Mammalian (human cell)
Isotypes Human IgG1
Bioactivity validation Validated in Monkeypox virus (MPV) A33 antigen protein binding affnity.ELISA validated as capture antibody and detection antibody. Pair recommendation with other A33 antibodies in A33 level test of Monkeypox virus (MPV) infectious diseases.
Tag hFc
Products description Anti-MPV (A33) human monoclonal neutralizing antibody (IgG1) is a potency validated Monkeypox virus (MPV) neutralizing antibody. It is a human IgG1 antibody produced by Mammalian (human cell). The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other A33 antibodies.
Reconized/Reactive Species Human
Purity Purity: ≥95% (SDS-PAGE)
Application This antibodies can either act as positive control in Monkeypox virus (MPV) related vaccines and neutralizing antibodies discovery and development, or act as a benchmark in Monkeypox virus (MPV) neutralization potency assay. ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.